
Echo IQ shares sink 42% as FDA upholds rejection
Key points
- The US FDA has upheld its decision not to clear Echo IQ’s EchoSolv HF heart failure AI tool, after reviewing the company’s appeal.
- Echo IQ shares fell 42.11% to close at $0.275.
- The company is weighing its options, including a new FDA application, while its separate EchoSolv AS tool remains cleared and on sale in the US.
Echo IQ (ASX:EIQ) shares fell 42.11% after the US Food and Drug Administration (FDA) upheld its decision not to clear the company’s EchoSolv HF heart failure AI tool, following a review of Echo IQ’s appeal.
The FDA had earlier found EchoSolv HF “not substantially equivalent” to devices already on the US market, and Echo IQ flagged in September that a new 510(k) submission was a possible outcome of its appeal.
The company said it is evaluating its options with its US regulatory and legal advisers, including engaging with the FDA, making a new 510(k) submission, or seeking further review under FDA procedures.
The ruling does not affect EchoSolv AS, the company’s AI tool for detecting aortic stenosis, which remains FDA-cleared and commercially available in the US.
Echo IQ said it has been preparing for a pre-submission meeting with the FDA and a possible new application, and will seek to confirm the analysis and clinical evidence the regulator needs, though it gave no timeline.
Following the announcement the Echo IQ share price was down 42.11% at $0.275.
Sydney-based Echo IQ develops AI software designed to help cardiologists make decisions, with its EchoSolv tools analysing heart ultrasound, or echocardiogram, data.
A 510(k) is the FDA process that lets a company sell a medical device in the US by showing it is substantially equivalent to one already on the market, so the ruling keeps EchoSolv HF off US sale for now.
Frequently asked questions
More from Australia
Australian Vintage names new CFO, starting January 2027
ASIC warns on QUFC Exchange, removes 20+ websites
WA Government commits $4m to life sciences hub
Count Financial wins Federal Court appeal in class action over advisor commissions
CurveBeam AI wins first China order for four scanners
Amplitude targets last east coast gas well in bid to boost Australian supply


